Riik: Kanada
keel: inglise
Allikas: Health Canada
METOPROLOL TARTRATE
ANGITA PHARMA INC.
C07AB02
METOPROLOL
50MG
TABLET
METOPROLOL TARTRATE 50MG
ORAL
100/500
Prescription
BETA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0111923002; AHFS:
APPROVED
2018-10-02
_AG-Metoprolol-L tablets _ _Page 1_ _ _ _of 41_ _ _ PRODUCTMONOGRAPH PR AG-METOPROLOL-L Metoprolol Tartrate Tablets USP 25mg, 50 mg and 100 mg film coated tablets, USP β-Adrenergic Receptor Blocking Agent Angita Pharma Inc 1310 rue Nobel Boucherville, Québec J4B 5H3, Canada Submission Control No: 266208 Date of Revision: August 10, 2022 _AG-Metoprolol-L tablets _ _Page 2_ _ _ _of 41_ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION .......................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................... 3 CONTRAINDICATIONS .................................................................................................... 4 WARNINGS AND PRECAUTIONS .................................................................................... 5 ADVERSE REACTIONS .................................................................................................. 10 DRUG INTERACTIONS .................................................................................................. 12 DOSAGE AND ADMINISTRATION ............................................................................... 18 OVERDOSAGE ................................................................................................................. 20 ACTION AND CLINICAL PHARMACOLOGY ............................................................. 21 STORAGE AND STABILITY .......................................................................................... 24 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................. 25 PART II: SCIENTIFIC INFORMATION .................................................................................. 26 PHARMACEUTICAL INFORMATION .......................................................................... 26 CLINICAL TRIALS ................................................................... Lugege kogu dokumenti